Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę "Merkelbach, Matthias" wg kryterium: Autor


Tytuł :
Down regulation and nuclear localization of human beta-defensin-1 in pleomorphic adenomas of salivary glands.
Autorzy :
Pantelis A; Department of Otorhinolaryngology/Surgery, University of Bonn, D-53105 Bonn, Germany. />Wenghoefer M
Haas S
Merkelbach-Bruse S
Pantelis D
Jepsen S
Bootz F
Winter J
Pokaż więcej
Źródło :
Oral oncology [Oral Oncol] 2009 Jun; Vol. 45 (6), pp. 526-30. Date of Electronic Publication: 2008 Sep 20.
Typ publikacji :
Journal Article
MeSH Terms :
Adenoma, Pleomorphic/*metabolism
Neoplasm Proteins/*metabolism
Salivary Gland Neoplasms/*metabolism
beta-Defensins/*metabolism
Adenoma, Pleomorphic/pathology ; Adult ; Aged ; Aged, 80 and over ; Case-Control Studies ; Cell Nucleus/metabolism ; Chronic Disease ; Down-Regulation ; Female ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction/methods ; RNA, Messenger ; Salivary Gland Neoplasms/pathology ; Sialadenitis/metabolism ; Sialadenitis/pathology ; Young Adult
Czasopismo naukowe
Tytuł :
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Autorzy :
Scheffler M; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Bos M; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Gardizi M; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
König K; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Michels S; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Fassunke J; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Heydt C; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Künstlinger H; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Ihle M; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Ueckeroth F; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Albus K; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Serke M; Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany.
Gerigk U; Clinic for Hematology, Oncology and Palliative Care, Malteser Hospital, Bonn, Germany.
Schulte W; Clinic for Hematology, Oncology and Palliative Care, Malteser Hospital, Bonn, Germany.
Töpelt K; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Nogova L; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Zander T; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Gastrointestinal Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Engel-Riedel W; Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany.
Stoelben E; Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany.
Ko YD; Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany.
Randerath W; Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany.
Kaminsky B; Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany.
Panse J; Department of Medicine IV, University Hospital RWTH Aachen, Aachen, Germany.
Becker C; Department of Medicine IV, University Hospital RWTH Aachen, Aachen, Germany.
Hellmich M; Institute of Medical Statistics, Informatics, and Epidemiology, University of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Heukamp LC; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Center for Integrated Oncology Köln Bonn, Cologne, Germany.Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Oncotarget [Oncotarget] 2015 Jan 20; Vol. 6 (2), pp. 1315-26.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Phosphatidylinositol 3-Kinases/*genetics
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Class I Phosphatidylinositol 3-Kinases ; Cohort Studies ; Exons/genetics ; Female ; Gene Frequency ; Genetic Heterogeneity ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Neoplasms, Second Primary/genetics ; Neoplasms, Second Primary/pathology ; Prognosis ; Survival Analysis
Czasopismo naukowe
Tytuł :
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Autorzy :
Scheffler M; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Schultheis A; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Teixido C; Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona, Spain.
Michels S; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Morales-Espinosa D; Institut d'Investigació en Ciències de la Salut, Germans Trias i Pujol, Badalona, Spain.
Viteri S; Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain.
Hartmann W; Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany.
Merkelbach-Bruse S; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Fischer R; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Schildhaus HU; Institute of Pathology, University Hospital of Göttingen, Göttingen, Germany.
Fassunke J; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Sebastian M; Department of Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany.
Serke M; Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany.
Kaminsky B; Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany.
Randerath W; Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany.
Gerigk U; Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany.
Ko YD; Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany.
Krüger S; Clinic for Pneumology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany.
Schnell R; Practice for Internistic Oncology and Hematology, Frechen, Germany.
Rothe A; Practice for Hematology and Oncology Mainka/Dietze/Rothe, Cologne, Germany.
Kropf-Sanchen C; Department II for Internal Medicine, University Hospital of Ulm, Ulm, Germany.
Heukamp L; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Rosell R; Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain.; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.
Büttner R; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Center for Integrated Oncology Köln Bonn, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Oncotarget [Oncotarget] 2015 Apr 30; Vol. 6 (12), pp. 10577-85.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*genetics
Lung Neoplasms/*genetics
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adenocarcinoma/drug therapy ; Adenocarcinoma/enzymology ; Adenocarcinoma of Lung ; Adult ; Aged ; Female ; Gene Rearrangement ; Genetic Variation ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/enzymology ; Male ; Middle Aged ; Prognosis ; Protein-Tyrosine Kinases/metabolism ; Proto-Oncogene Proteins/metabolism ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
Autorzy :
Scheffler M; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Köln Bonn, Institute of Pathology, University Hospital of Cologne, Cologne, Germany; ‡Department of Translational Genomics, Center for Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany; §Lung Cancer Group Cologne, Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ‖Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ¶Center for Integrated Oncology Köln Bonn, Institute of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and #Institute of Hematopathology Hamburg, Hamburg, Germany.
Merkelbach-Bruse S
Bos M
Fassunke J
Gardizi M
Michels S
Groneck L
Schultheis AM
Malchers F
Leenders F
Kobe C
König K
Heukamp LC
Sos ML
Thomas RK
Büttner R
Wolf J
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2015 Jun; Vol. 10 (6), pp. e40-3.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Proto-Oncogene Proteins c-met/*genetics
Drug Resistance, Neoplasm ; Gene Amplification ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
Autorzy :
König K; Institute of Pathology, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Cologne/Bonn, University Hospital of Cologne, Cologne, Germany; ‡Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; §Labor Dr. Quade und Kollegen GmbH, Cologne, Germany; ‖Institute of Human Genetics, University of Cologne, Cologne, Germany; ¶Targos Molecular Pathology GmbH, Kassel, Germany; #Department of Translational Genomics, University of Cologne, Cologne, Germany; **Cologne Center for Genomics, Cologne, Germany; ††GENterprise GENOMICS GmbH, Mainz, Germany; ‡‡Bristol-Myers Squibb R&D, Princeton, New Jersey; §§Evangelische Kliniken Johanniter, Bonn, Germany; ‖‖Malteser Krankenhaus, Lung Cancer Center, Bonn, Germany; ¶¶Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; ##Institute for Hematopathology Hamburg, Hamburg, Germany; and ***New Oncology, Cologne, Germany.
Peifer M
Fassunke J
Ihle MA
Künstlinger H
Heydt C
Stamm K
Ueckeroth F
Vollbrecht C
Bos M
Gardizi M
Scheffler M
Nogova L
Leenders F
Albus K
Meder L
Becker K
Florin A
Rommerscheidt-Fuss U
Altmüller J
Kloth M
Nürnberg P
Henkel T
Bikár SE
Sos ML
Geese WJ
Strauss L
Ko YD
Gerigk U
Odenthal M
Zander T
Wolf J
Merkelbach-Bruse S
Buettner R
Heukamp LC
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2015 Jul; Vol. 10 (7), pp. 1049-57.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*genetics
Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*genetics
Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Cohort Studies ; DNA, Neoplasm/analysis ; DNA, Neoplasm/genetics ; DNA, Neoplasm/isolation & purification ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/therapy ; Polymerase Chain Reaction/methods ; Sequence Analysis, DNA/methods
Czasopismo naukowe
Tytuł :
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Autorzy :
Michels S; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
Scheel AH; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Scheffler M; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
Schultheis AM; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Gautschi O; Department for Medical Oncology, Lucerne Cantonal Hospital, Lucerne, Switzerland.
Aebersold F; Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland.
Diebold J; Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland.
Pall G; Department for Internal Medicine, Haematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria.
Rothschild S; Department for Oncology, University Hospital Basel, Basel, Switzerland.
Bubendorf L; Department for Cytopathology, University Hospital Basel, Basel, Switzerland.
Hartmann W; Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany.
Heukamp L; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Schildhaus HU; Institute of Pathology, University Hospital of Göttigen, Göttingen, Germany.
Fassunke J; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Ihle MA; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Künstlinger H; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Heydt C; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Fischer R; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
Nogovà L; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
Mattonet C; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
Hein R; Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany.
Adams A; Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany.
Gerigk U; Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany.
Schulte W; Departent for Pulmonology Cardiology and Allergology, Johanniter Hospital, Bonn, Germany.
Lüders H; Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany.
Grohé C; Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany.
Graeven U; Department for Hematology, Oncology and Gastroenterology, Maria Hilf Hospital Mönchengladbach, Mönchengladbach, Germany.
Müller-Naendrup C; Private Practice for Oncology, Medical Centre II (Martinus Höfe), Olpe, Germany.
Draube A; Department for Internal Medicine, St. Vinzenz Hospital Cologne, Cologne, Germany.
Kambartel KO; Department for Pulmonology and Allergology, Bethanien Hospital Moers, Moers, Germany.
Krüger S; Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany.
Schulze-Olden S; Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany.
Serke M; Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany.
Engel-Riedel W; Lung Clinic Merheim, Hospitals of Cologne, Cologne, Germany.
Kaminsky B; Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany.
Randerath W; Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany.
Merkelbach-Bruse S; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2016 Jan; Vol. 11 (1), pp. 122-7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Adenocarcinoma/*genetics
Biomarkers, Tumor/*genetics
Carcinoma, Squamous Cell/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins c-ret/*genetics
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/pathology ; Europe ; Female ; Follow-Up Studies ; Humans ; In Situ Hybridization, Fluorescence ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Oncogene Proteins, Fusion/genetics ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
Autorzy :
Ortiz-Cuaran S; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
Scheffler M; Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
Plenker D; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Molecular Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Dahmen L; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
Scheel AH; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Fernandez-Cuesta L; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
Meder L; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Lovly CM; Department of Medicine, Vanderbilt University, Nashville, Tennessee.
Persigehl T; Radiology Department, University Hospital Cologne, Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Bos M; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
Michels S; Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
Fischer R; Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
Albus K; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
König K; Labor Dr. Quade und Kollegen GmbH, Cologne, Germany.
Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Goettingen, Germany.
Fassunke J; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Ihle MA; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Pasternack H; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. Pathology of the University Hospital of Luebeck and Leibniz Research Center Borstel, Lübeck and Borstel, Germany.
Heydt C; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Becker C; Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
Altmüller J; Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
Ji H; Key Laboratory of Systems Biology, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Science, Shanghai, China. School of Life Science and Technology, Shanghai Tech University, Shanghai, China.
Müller C; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
Florin A; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Heuckmann JM; NEO New Oncology AG, Cologne, Germany.
Nuernberg P; Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
Ansén S; Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
Heukamp LC; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. NEO New Oncology AG, Cologne, Germany.
Berg J; Institute for Theoretical Physics. University of Cologne, Cologne, Germany.
Pao W; Department of Medicine, Vanderbilt University, Nashville, Tennessee.
Peifer M; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Buettner R; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. .
Wolf J; Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany. .
Thomas RK; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. .
Sos ML; Molecular Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Oct 01; Vol. 22 (19), pp. 4837-4847. Date of Electronic Publication: 2016 Jun 01.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Agents/*therapeutic use
Drug Resistance, Neoplasm/*genetics
Lung Neoplasms/*drug therapy
Acrylamides/therapeutic use ; Adenocarcinoma of Lung ; Aged ; Aniline Compounds/therapeutic use ; ErbB Receptors/antagonists & inhibitors ; Female ; Humans ; Male ; Middle Aged ; Pyrimidines/therapeutic use
Czasopismo naukowe
Tytuł :
P2.03b-028 Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM: Topic: Biomarkers
Autorzy :
Kostenko, Anna
Pokaż więcej
Źródło :
In Journal of Thoracic Oncology January 2017 12(1) Supplement:S950-S951
Czasopismo naukowe
Tytuł :
ALK mutation as a potential mechanism of acquired resistance to crizotinib in an ALK -rearranged inflammatory myofibroblastic tumor.
Autorzy :
Michels SYF; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 2Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Scheel AH; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wündisch T; 4Comprehensive Cancer Center Düsseldorf, University Hospital of Düsseldorf, Düsseldorf, Germany.
Heuckmann JM; NEO New Oncology AG, Cologne, Germany.
Menon R; NEO New Oncology AG, Cologne, Germany.
Puesken M; 6Department of Radiology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Kobe C; 7Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Pasternack H; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Heydt C; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Scheffler M; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 2Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Fischer R; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 2Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Schultheis AM; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Heukamp L; NEO New Oncology AG, Cologne, Germany.; Institute of Hematopathology, Hamburg, Germany.
Büttner R; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 3Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wolf J; 1Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany.; 2Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
NPJ precision oncology [NPJ Precis Oncol] 2017 Mar 20; Vol. 1 (1), pp. 4. Date of Electronic Publication: 2017 Mar 20 (Print Publication: 2017).
Typ publikacji :
Case Reports
Raport
Tytuł :
Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non-Small Cell Lung Carcinoma (NSCLC).
Autorzy :
Frank R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Merkelbach-Bruse S; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Ihle MA; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Kron A; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Rauer M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.; Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD) Research Center and Systems Biology of Ageing Cologne, University of Cologne, Cologne, Germany.
Ueckeroth F; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
König K; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Michels S; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Fischer R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Eisert A; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Fassunke J; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Heydt C; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Serke M; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany.
Ko YD; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany.
Gerigk U; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Marien-Hospital Bonn, GFO Clinics Bonn, Bonn, Germany.
Geist T; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Center Practice for Lung and Bronchial Diseases, Düsseldorf, Germany.
Kaminsky B; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Clinic for Pulmonology and Allergology, Bethanien Hospital Solingen, Solingen, Germany.
Heukamp LC; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Clement-Ziza M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.; Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD) Research Center and Systems Biology of Ageing Cologne, University of Cologne, Cologne, Germany.
Büttner R; Network Genomic Medicine (Lung Cancer), Cologne, Germany.; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. .; Network Genomic Medicine (Lung Cancer), Cologne, Germany.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Jul 01; Vol. 24 (13), pp. 3087-3096. Date of Electronic Publication: 2018 Apr 03.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Carcinoma, Non-Small-Cell Lung/*genetics
Carcinoma, Non-Small-Cell Lung/*pathology
Kelch-Like ECH-Associated Protein 1/*genetics
Lung Neoplasms/*genetics
Lung Neoplasms/*pathology
NF-E2-Related Factor 2/*genetics
Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Cell Line, Tumor ; Female ; Genetic Association Studies ; Genetic Predisposition to Disease ; High-Throughput Nucleotide Sequencing ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Kelch-Like ECH-Associated Protein 1/metabolism ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Male ; NF-E2-Related Factor 2/metabolism ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1 -Rearranged NSCLC.
Autorzy :
Michels S; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Scheffler M; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Wagener S; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Plenker D; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Scheel A; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Nogová L; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Schultheis A; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Fischer RN; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Abdulla DSY; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Riedel R; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Bunck A; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Kobe C; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Baus W; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Merkelbach-Bruse S; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Sos ML; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Büttner R; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Wolf J; All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
JCO precision oncology [JCO Precis Oncol] 2018 Nov; Vol. 2, pp. 1-6.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Overcoming EGFR -mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
Autorzy :
Fassunke J; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Müller F; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Keul M; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Michels S; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Dammert MA; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Schmitt A; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
Plenker D; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Lategahn J; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Heydt C; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Brägelmann J; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Tumbrink HL; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Alber Y; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Klein S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Weyertal 115b, 50931, Cologne, Germany.
Heimsoeth A; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Dahmen I; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Ihle MA; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Priesner V; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Scheel AH; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Wagener S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Kron A; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Frank K; Section Pneumology, Clinic III of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Garbert K; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Persigehl T; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Püsken M; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Haneder S; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Schaaf B; Hospital Dortmund gGmbH, Muensterstrasse 240, 44145, Dortmund, Germany.
Rodermann E; Onkologie Rhein-Sieg, Schloßstraße 18, 53840, Troisdorf, Germany.
Engel-Riedel W; Department of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany.
Felip E; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Smit EF; Thoracic Oncology Service, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Merkelbach-Bruse S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Reinhardt HC; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
Kast SM; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Wolf J; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
Rauh D; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany. .
Büttner R; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
Sos ML; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2018 Nov 07; Vol. 9 (1), pp. 4655. Date of Electronic Publication: 2018 Nov 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm/*drug effects
ErbB Receptors/*antagonists & inhibitors
Piperazines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Acrylamides ; Aniline Compounds ; Animals ; Cell Line, Tumor ; Disease Progression ; ErbB Receptors/chemistry ; ErbB Receptors/metabolism ; Female ; Humans ; Kinetics ; Mice ; Mice, Nude ; Mutation/genetics ; NIH 3T3 Cells ; Piperazines/chemistry ; Protein Binding/drug effects ; Protein Conformation ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Autorzy :
Quaas A; Institute of Pathology, University of Cologne, Cologne, Germany. .
Heydt C; Institute of Pathology, University of Cologne, Cologne, Germany.
Waldschmidt D; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Alakus H; Department of Visceral Surgery, University of Cologne, Cologne, Germany.
Zander T; Department of Oncology and Hematology, University of Cologne, Cologne, Germany.
Goeser T; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Kasper P; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Bruns C; Department of Visceral Surgery, University of Cologne, Cologne, Germany.
Brunn A; Institute of Neuropathology, University of Cologne, Cologne, Germany.
Roth W; Institute of Pathology, University of Mainz, Mainz, Germany.
Hartmann N; Institute of Pathology, University of Mainz, Mainz, Germany.
Bunck A; Department of Radiology, University of Cologne, Cologne, Germany.
Schmidt M; Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
Buettner R; Institute of Pathology, University of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
BMC gastroenterology [BMC Gastroenterol] 2019 Feb 04; Vol. 19 (1), pp. 21. Date of Electronic Publication: 2019 Feb 04.
Typ publikacji :
Journal Article
MeSH Terms :
Intestine, Small*
Microsatellite Instability*
Precision Medicine*
Adenocarcinoma/*therapy
BRCA2 Protein/*genetics
Intestinal Neoplasms/*therapy
Receptor, ErbB-2/*genetics
Ubiquitin-Protein Ligases/*genetics
Adenocarcinoma/genetics ; Aged ; DNA Repair/genetics ; Humans ; Intestinal Neoplasms/genetics ; Middle Aged ; Mutation
Czasopismo naukowe
Tytuł :
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[ F]fluoroethyl)-L-tyrosine PET.
Autorzy :
Abdulla DSY; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Brandes V; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Ruge M; Center for Integrated Oncology Köln, Bonn, Germany; Department of Stereotaxy and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Kunze S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Michels S; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Fischer R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Riedel R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Büttner R; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Persigehl T; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiology, University Hospital of Cologne, Cologne, Germany.
Grau S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Galldiks N; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
Drzezga A; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Kobe C; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2019 Mar; Vol. 20 (2), pp. e148-e151. Date of Electronic Publication: 2018 Nov 05.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Brain Neoplasms/*diagnosis
Carcinoma, Non-Small-Cell Lung/*diagnosis
Erlotinib Hydrochloride/*therapeutic use
Lung Neoplasms/*diagnosis
Tyrosine/*analogs & derivatives
Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Mutation/genetics ; Positron-Emission Tomography
Czasopismo naukowe
Tytuł :
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Autorzy :
Michels S; University Hospital of Cologne, Cologne, Germany.
Heydt C; University Hospital of Cologne, Cologne, Germany.
van Veggel B; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Deschler-Baier B; University Hospital of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Pardo N; Vall d'Hebron University Hospital, Barcelona, Spain.
Monkhorst K; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rüsseler V; University Hospital of Cologne, Cologne, Germany.
Stratmann J; University Hospital of Frankfurt, Frankfurt, Germany.
Griesinger F; Pius Hospital Oldenburg and Lung Cancer Network NOWEL, Oldenburg, Germany.
Steinhauser S; University of Cologne, Cologne, Germany.
Kostenko A; University Hospital of Cologne, Cologne, Germany.
Diebold J; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Fassunke J; University Hospital of Cologne, Cologne, Germany.
Fischer R; University Hospital of Cologne, Cologne, Germany.
Engel-Riedel W; Lung Clinic Merheim and Hospitals of Cologne, Cologne, Germany.
Gautschi O; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Geissinger E; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Haneder S; University Hospital of Cologne, Cologne, Germany.
Ihle MA; University Hospital of Cologne, Cologne, Germany.
Kopp HG; Robert Bosch Centrum für Tumorerkrankungen, Stuttgart, Germany.
de Langen AJ; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Martinez-Marti A; Vall d'Hebron University Hospital, Barcelona, Spain.
Nogova L; University Hospital of Cologne, Cologne, Germany.
Persigehl T; University Hospital of Cologne, Cologne, Germany.
Plenker D; University Hospital of Cologne, Cologne, Germany.
Puesken M; University Hospital of Cologne, Cologne, Germany.
Rodermann E; Private practice in Hematology and Oncology, Troisdorf, Germany.
Rosenwald A; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Scheel AH; University Hospital of Cologne, Cologne, Germany.
Scheffler M; University Hospital of Cologne, Cologne, Germany.
Spengler W; University Hospital of Tübingen. Tübingen, Germany.
Seggewiss-Bernhardt R; Sozialstiftung Bamberg, Bamberg, Germany.
Brägelmann J; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Sebastian M; University Hospital of Frankfurt, Frankfurt, Germany.
Vrugt B; University Hospital Zurich, Zurich, Switzerland.
Hellmich M; University of Cologne, Cologne, Germany.
Sos ML; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Heukamp LC; Hematopathology Hamburg and Lung Cancer Network NOWEL, Hamburg, Germany.
Felip E; Vall d'Hebron University Hospital, Barcelona, Spain.
Merkelbach-Bruse S; University Hospital of Cologne, Cologne, Germany.
Smit EF; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Büttner R; University Hospital of Cologne, Cologne, Germany.
Wolf J; University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
JCO precision oncology [JCO Precis Oncol] 2019 Mar 27; Vol. 3. Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Autorzy :
Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Hein R; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Scheel AH; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Siemanowski J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Brägelmann J; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abedpour N; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Ueckeroth F; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Schüller M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Pasternack H; Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences.
Heydt C; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Serke M; Lung Clinic Hemer, Department for Pulmonology and Thoracic Oncology, Hemer, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schulte W; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ko YD; Evangelical Clinics of Bonn, Johanniter Hospital, Bonn, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Lorenz J; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Sauerland I; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Hagmeyer L; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Grohé C; Evangelic Lung Clinic Berlin, Department of Respiratory Diseases, Berlin, Germany.
Eisert A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Frank R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gogl L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schaepers C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Hellmich M; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Thomas RK; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Peifer M; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Sos ML; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Apr; Vol. 14 (4), pp. 606-616. Date of Electronic Publication: 2018 Dec 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation
Czasopismo naukowe
Tytuł :
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Autorzy :
Michels S; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Massutí B; Department of Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain.
Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Göttingen, Germany and Targos Molecular Pathology, Kassel, Germany.
Franklin J; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Sebastian M; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Grohé C; Department of Pneumology, Protestant Lung Hospital Berlin, Berlin, Germany.
Rodriguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Abdulla DSY; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Bischoff H; Thoraxonkologie, Thoraxklinik, Heidelberg, Germany.
Brandts C; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Carcereny E; Servei d'Oncologia Mèdica, Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Carretera de Canyet, Badalona, Spain.
Corral J; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; prior affiliation during the trial: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Dingemans AC; Department for Oncology, Maastricht University Medical Center, Maastricht, Netherlands.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Fassunke J; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Gardizi M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Heukamp L; Institute of Hematopatholgy Hamburg, Hamburg, Germany, and Lung Cancer Network NOWEL, Oldenburg, Germany.
Insa A; Hospital Clínico Universitario de Valencia, València, Spain.
Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Menon R; NEO New Oncology GmbH, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
Reck M; Department for Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Großhansdorf, Germany.
Riedel R; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rothschild SI; University Hospital Basel, Department Internal Medicine, Medical Oncology, Basel, Switzerland.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Schmalz P; Clinical Trials Centre Cologne (CTCC) Medical Faculty, University of Cologne, Cologne, Germany.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Limburg M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Spain.
Karachaliou N; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Hellmich M; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Büttner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jul; Vol. 14 (7), pp. 1266-1276. Date of Electronic Publication: 2019 Apr 09.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Brain Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/genetics ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Survival Rate
Czasopismo naukowe
Tytuł :
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Autorzy :
Riedel R; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Heydt C; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Siemanowski J; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Kobe C; Department for Nuclear Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Bunck A; Department for Radiology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Schäfer S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Fischer RN; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Abdulla DSY; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Nogová L; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Koleczko S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Jul; Vol. 133, pp. 20-22. Date of Electronic Publication: 2019 May 06.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Mutation/*genetics
Proto-Oncogene Proteins c-met/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adenocarcinoma of Lung/genetics ; Biomarkers, Tumor/genetics ; Carcinogenesis/genetics ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Amplification ; Humans ; Lung Neoplasms/genetics ; Middle Aged ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
Autorzy :
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lehmann U; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Leichsenring J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Glade J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Stögbauer F; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Lehmann A; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Trautmann M; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Kumbrink J; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Jung A; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Dietmaier W; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evert M; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Kreipe H; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Kirchner T; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Wardelmann E; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Quality Initiative in Pathology (QuiP), Berlin, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2020 Mar; Vol. 59 (3), pp. 178-188. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*
Genetic Testing*/methods
High-Throughput Nucleotide Sequencing*/methods
High-Throughput Nucleotide Sequencing*/standards
Receptors, Nerve Growth Factor/*genetics
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Clinical Decision-Making ; Disease Management ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Infant ; Male ; Middle Aged ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/metabolism ; Receptors, Nerve Growth Factor/metabolism ; Reproducibility of Results ; Workflow ; Young Adult
Czasopismo naukowe
Tytuł :
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Autorzy :
Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
von Levetzow C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wömpner C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Bitter E; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Weber JP; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Westphal T; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Kern J; KWM Missio Clinic, Würzburg, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Jun; Vol. 144, pp. 40-48. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Kelch-Like ECH-Associated Protein 1 ; MAP Kinase Kinase 1/genetics ; Mutation ; NF-E2-Related Factor 2 ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics
Czasopismo naukowe
Tytuł :
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Autorzy :
Nogova L; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Mattonet C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.; Onkologische Praxis Moers, Moers, Germany.
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Taubert M; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Gardizi M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Sos ML; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Fischer RN; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Limburg M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Abdulla DSY; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Persigehl T; Faculty of Medicine and University Hospital Cologne, Institute for Diagnostics und Intervention Radiology, University of Cologne, Cologne, Germany.
Kobe C; Faculty of Medicine and University Hospital Cologne, Department for Nuclear Medicine, University of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Faculty of Medicine and University Hospital Cologne, Institute for Pathology, University of Cologne, Cologne, Germany.
Franklin J; Faculty of Medicine, Institute for Medical Statistics and Bioinformatics, University of Cologne, Cologne, Germany.
Backes H; Max Planck Institute for Metabolism Research, Cologne, Germany.
Schnell R; Praxis for Medical Oncology and Haematology (PIOH), Frechen, Germany.
Behringer D; Heamatology and Oncology, Augusta Hospital, Bochum, Germany.
Kaminsky B; Bethanien Hospital, Solingen, Germany.
Eichstaedt M; Medical Oncology and Haematology, St. Marien Hospital, Düren, Germany.
Stelzer C; Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg, Germany.
Kinzig M; Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg, Germany.
Sörgel F; Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg, Germany.
Tian Y; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Junge L; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Suleiman AA; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Frechen S; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Rokitta D; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Ouyang D; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.; Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
Fuhr U; Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Buettner R; Faculty of Medicine and University Hospital Cologne, Institute for Pathology, University of Cologne, Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2020 Jul; Vol. 9 (14), pp. 4991-5007. Date of Electronic Publication: 2020 May 21.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Everolimus/*therapeutic use
Fluorodeoxyglucose F18/*metabolism
Lung Neoplasms/*drug therapy
Positron-Emission Tomography/*methods
Proto-Oncogene Proteins p21(ras)/*metabolism
Sorafenib/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Everolimus/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Sorafenib/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies